AstraZeneca and MedImmune, our global biologics research and development arm, have been voted one of the top science employers worldwide, in the prestigious Science 2017 Top Employers Survey1.
Our key strengths, as highlighted by survey participants, focused on our aspirational work culture, our dynamic and intellectually challenging environment, and our commitment to collaboration, which our scientists enjoy at research centres across the globe.
Many are exploring alternatives to traditional ‘per pill’ arrangements underlying reimbursement. This holds implications for pharma manufacturers.
OCTOBER 26, 2017
Host: UM BioPark & Wexford Science + Technology
Location: UM BioPark Life Sciences Conference Centeer 801 W. Baltimore Street Baltimore Maryland 21201
Time: 5:00pm to 6:30pm
Please join the BioPark’s Monthly Networking Event. Mingle with BioPark tenants, and UMB faculty and staff.
Thursday, December 07, 2017 5:30 PM – 7:30 PM EST
Horseshoe Casino Baltimore 1525 Russell Street Baltimore, MD 21230
We’re excited to announce MTC’s first annual Black & White Affair. Our exclusive holiday party will feature gourmet appetizers, music, unique silent auction items and cocktails as you help fund internships through the inMD platform.
Since the launch of the BioPark Initiative in 2003, the BioPark has grown to include nearly three dozen companies with more than 1,000 employees. Looking out a fifth-floor window of BioPark Building One, BioPark Senior Vice President Jane Shaab pointed out other BioPark facilities, such as the Maryland Proton Treatment Center, the Maryland Forensic Medical Center, the newly added Lion Brothers Building, and the construction site where work has begun on BioPark Building Three, a facility that will double the number of BioPark employees.
The Food and Drug Administration on Wednesday approved the second in a radically new class of treatments that genetically reboot a patient’s own immune cells to kill cancer.
Inova Health System is bringing Northern Virginia tech investor Rick Gordon into the fold.
This is the latest in my “superstar effect” series. Richard Florida posted an interesting analysis of venture capital investments over at City Lab.
Drug accelerator Cydan has gained a $34 million injection as it eyes deeper inroads into rare diseases for its second fund.
Germantown-based bioengineering company Intrexon Corp. will have access to up to $100 million of new capital through a deal with an affiliate company controlled by its founder and chairman, Randal “RJ” Kirk.
